Efficacy of Orally Administered T-705 Pyrazine Analog on Lethal West Nile Virus Infection in Rodents

Authors

John D. Morrey, Utah State UniversityFollow
B S. Taro
V Siddharthan, Utah State UniversityFollow
H Wang, Utah State UniversityFollow
Donald F. Smee, Utah State UniversityFollow
A J. Christensen
Y Furuta

Document Type

Article

Journal/Book Title/Conference

Antiviral Res

Volume

80

Publication Date

2008

First Page

377

Last Page

379

Abstract

We describe herein that a pyrazine derivative, T-705 (6-fluoro-3-hydroxy-2-pyrazinecarboxamide), is protective for a lethal West Nile virus infection in rodents. Oral T-705 at 200 mg/kg administered twice daily beginning 4 h after subcutaneous (s.c.) viral challenge protected mice and hamsters against WNV-induced mortality, and reduced viral protein expression and viral RNA in brains. The minimal effective oral dose was between 20 and 65 mg/kg when administered twice a day beginning 1 day after viral s.c. challenge of mice. Treatment could be delayed out to 2 days after viral challenge to still achieve efficacy in mice. Further development of this compound should be considered for treatment of WNV.

Recommended Citation

Morrey, J. D., B. S. Taro, V. Siddharthan, H. Wang, D. F. Smee, A. J. Christensen, and Y. Furuta. 2008. Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. Antiviral Res 80:377-379. PMID18762216 PMCPMC2587511